[1] Saïd-Sadier N, Ojcius DM. Alarmins, inflammasomes and immunity. Biomed J, 2012, 35(6): 437-449.
[2] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol, 2010, 11(5): 373-384.  doi: 10.1038/ni.1863
[3] Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol, 2013, 33 Suppl 1: S79-84.
[4] Woods DC, White YA, Dau C, et al. TLR4 activates NF-κB in human ovarian granulosa tumor cells. Biochem Biophys Res Commun, 2011, 409(4): 675-680.  doi: 10.1016/j.bbrc.2011.05.063
[5] Sato Y, Goto Y, Narita N, et al. Cancer cells expressing Toll-like receptors and the tumor microenvironment. Cancer Microenviron, 2009, 2 Supple1: S205-214.
[6] Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res, 2006, 66(7): 3859-3868.  doi: 10.1158/0008-5472.CAN-05-3948
[7] Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer, 2009, 9(1): 57-63.  doi: 10.1038/nrc2541
[8] Mittal D, Saccheri F, Vénéreau E, et al. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J, 2010, 29(13): 2242-2252.  doi: 10.1038/emboj.2010.94
[9] Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 1997, 388(6640): 394-397.  doi: 10.1038/41131
[10] Gurung P, Malireddi RK, Anand PK, et al. Toll or interleukin-1 receptor(TIR)domain-containing adaptor inducing interferon-β(TRIF)-mediated caspase-11 protease production integrates Toll-like receptor 4(TLR4)protein- and Nlrp3 inflammasome-mediated host defense against enteropathogens. J Biol Chem, 2012, 287(41): 34474-34483.  doi: 10.1074/jbc.M112.401406
[11]

Jin B, Sun T, Yu XH, et al. The effects of TLR activation on T-cell development and differentiation[J/OL]. Clin Dev Immunol, 2012, 2012: E1 [2013-05-15]. http://www.hindawi.com/journals/cdi/2012/836485. [published online ahead of print Jun 7, 2012].
[12] Bauer S, Müller T, Hamm S. Pattern recognition by Toll-like receptors. Adv Exp Med Biol, 2009, 653(1): 15-34.
[13] Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun, 2009, 388(4): 621-625.
[14] Huang B, Zhao J, Unkeless JC, et al. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene, 2008, 27(2): 218-224.  doi: 10.1038/sj.onc.1210904
[15] Andreani V, Gatti G, Simonella L, et al. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res, 2007, 67(21): 10519-10527.  doi: 10.1158/0008-5472.CAN-07-0079
[16] Wolska A, Lech-Marańda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett, 2009, 14(2): 248-272.
[17] Gambara G, De Cesaris P, De Nunzio C, et al. Toll-like receptors in prostate infection and cancer between bench and bedside. J Cell Mol Med, 2013, 17(6): 713-722.  doi: 10.1111/jcmm.12055
[18] Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res, 2005, 65(12): 5009-5014.  doi: 10.1158/0008-5472.CAN-05-0784
[19] Yang H, Zhou H, Feng P, et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res, 2010, 29: 92.  doi: 10.1186/1756-9966-29-92
[20] Chochi K, Ichikura T, Kinoshita M. et al. Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin Cancer Res, 2008, 14(10): 2909-2917.  doi: 10.1158/1078-0432.CCR-07-4467
[21] Wild CA, Bergmann C, Fritz G, et al. HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. Int Immunol, 2012, 24(8): 485-494.  doi: 10.1093/intimm/dxs051
[22] Del Prete A, Allavena P, Santoro G, et al. Molecular pathways in cancer-related inflammation. Biochem Med(Zagreb), 2011, 21(3): 264-275.
[23] Luo Y, Chihara Y, Fujimoto K, et al. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer, 2013, 49(3): 741-751.  doi: 10.1016/j.ejca.2012.09.016
[24] Riddell JR, Bshara W, Moser MT, et al. Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res, 2011, 71(5): 1637-1646.  doi: 10.1158/0008-5472.CAN-10-3674
[25] Johnson GB, Brunn GJ, Platt JL. Cutting edge: an endogenous pathway to systemic in flammatory response syndrome(SIRS)-like reactions through Toll-like receptor 4. J Immunol, 2004, 172(1): 20-24.
[26] Wang L, Zhao Y, Qian J, et al. Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion. Cancer, 2013, 119(4): 782-791.
[27] Apetoh L, Tesniere A, Ghiringhelli F, et al. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res, 2008, 68(11): 4026-4030.  doi: 10.1158/0008-5472.CAN-08-0427
[28] Hua D, Liu MY, Cheng ZD, et al. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival and tumorigenicity. Mol Immunol, 2009, 46(15): 2876-2884.
[29] Tang X, Zhu Y. TLR4 signaling promotes immune escape of human colon cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Oncol Res, 2012, 20(1): 15-24.
[30] Sun Z, Luo Q, Ye D, et al. Role of toll-like receptor 4 on the immune escape of human oral squamous cell carcinoma and resistance of cisplatin-induced apoptosis. Mol Cancer, 2012, 11: 33.  doi: 10.1186/1476-4598-11-33
[31] Szajnik M, Szczepanski MJ, Czystowska M, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene, 2009, 28(49): 4353-4363.  doi: 10.1038/onc.2009.289
[32] Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemo-therapy and radiotherapy. Nat Med, 2007, 13(9): 1050-1059.
[33] 卢良杰, 董娟聪, 张聪, 等. Toll样受体4对肿瘤细胞放射敏感性的影响.中华放射医学与防护杂志, 2012, 32(6): 583-587.  doi: 10.3760/cma.j.issn.0254-5098.2012.06.006
[34] Cao N, Li S, Wang Z, et al. NF-κB-mediated HER2 overexpression in radiation-adaptive resistance. Radiat Res, 2009, 171(1): 9-21.
[35]

Multhoff G, Radons J. Radiation, inflammation, and immune responses in cancer[J/OL]. Front Oncol, 2012, 2: E1[2013-05-15]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366472.[published online ahead of print Jun 4, 2012].
[36] Galluzzi L, Vacchelli E, Eggermont A, et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology, 2012, 1(5): 699-716.